Toxic Effects of Griseofulvin: Disease Models, Mechanisms, and Risk Assessment

References

• Adamson R. H., Sieber S. M. Carcinogenic potential of drugs. J. Environm. Pathol. Toxicol. Oncol. 1981, 3/4: 377–385
   Google Scholar
• Adler I. D., Brewen J. G. Effects of chemicals on chromosome aberrations production in male and female germ cells, A. Hollaender, 1982; VII: 1–35, Chemical Mutagens—Principles and Methods for their Detection
   Google Scholar
• Albertini S., Brunner M., Würgler F. Analysis of the six additional chemicals forin vitro analysis of the European economic communities (EEC) aneuploidy programme usingSaccharomyces Cervisiae D 61 M and thein vitro porcine brain tubulin assembly assay. Env. Molec. Mutagen. 1993; 21: 180–192
   PubMedGoogle Scholar
• Amacher D. E., Zelljadt I. The morphological transformation of Syrian hamster embryo cells by chemicals reportedly nonmutagenic to. Salmonella typhimurium, Carcinogenesis 1983; 4: 291–296
   Google Scholar
• Anthony H. M., Kenny T. E. Drugs in the etiology of cancer. A retrospective study. Int. J. Epidem. 1982; 11: 336–344
   PubMedGoogle Scholar
• Atkinson R. M., Bedford C., Child K. J. Effect of particle size on blood Griseofulvin levels in man. Nature 1962; 193: 588–589
   PubMed Web of Science ®Google Scholar
• Aujezdska A. Effect of Griseofulvin on mouse fetal skeleton. Cesk. Hyg. 1978; 23: 5–21
   Google Scholar
• Axelson O. A review of porphyria and cancer and the missing link with human exposure to hexachlorbenzene. C. R. Morris, J. R. P. Cabral. Publ, Lyon 1985; 77: 585–589, Hexachlorbenzene: Proceedings of an International SymposiumIARC Sci.
   Google Scholar
• Axelson O., Hardell L., Saracci R., Simontano L. Epidemiological studies in porphyrias. C. R. Morris, J. R. P. Cabral. Publ, Lyon 1985; 77: 593–594, Hexachlorbenzene: Proceedings of an International SymposiumIARC Sci.
   Google Scholar
• Barich L. L., Schwan J., Barich D. Oral Griseofulvin: a cocarcinogenic agent to methylcholanthrene induced cutaneous tumors. Cancer Res. 1962; 22: 53–55
   PubMedGoogle Scholar
• Barich L. L., Schwarz J., Barich D. J., Horowitz M. G. Toxic liver damage in mice after prolonged intake of elevated doses of Griseofulvin. Antibiot. Chemother. 1961; 11: 566–568
   Google Scholar
• Barrett W., Bianchine J. R. The bioavailability of ultramicrosize Griseofulvin tablets in man. Curr. Ther. Res. 1975; 18: 501–509
   PubMedGoogle Scholar
• Bedford C., Busfield D., Child K. J., McGregor I., Sutherland P., Tomich E. G. Studies on the biological disposition of Griseofulvin an oral antifungal agent. Arch. Dermatol. 1960; 81: 735–745
   PubMed Web of Science ®Google Scholar
• Benedict W. F., Murphree A. L., Banerjee A., Spina C. A., Sparkes M. C., Sparkes R. S. Patient with chromosome 13 deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science 1983; 219: 973–975
   PubMed Web of Science ®Google Scholar
• Bengtsson N. O., Hardell L. Porphyrias, porphyrins and hepatocellular cancer. Br. J. Cancer 1986; 54: 115–117
   PubMed Web of Science ®Google Scholar
• Bennett J. E. Antimicrobial agents. Goodman and Gilman's. The Pharmacological Basis of Therapeutics8th, A. Gilman, A. S. Nies, P. Taylor, 1990; 1173–1174, Macmillan
   Google Scholar
• Berman A., Franklin R. L. Precipitation of acute intermittent porphyria by griseofulvin therapy. J. Am. Med. Assoc. 1965; 192: 1005–1007
   Google Scholar
• Berman J., Brown A. Incidence of hepatoma in porphyria cutanea tarda. Rev. Czech. Med. 1962; 8: 290
   PubMedGoogle Scholar
• Beukeveld G J., Walthers B. G., vanSaene J. J.M., deHaan T. H.I.J., Ruyter-Buitenhuis L. W. Patterns of porphyrin exceretion in feces as determined by liquid chromatography: reference values and the effect of flora suppression. Clin. Chem. 1987; 31: 2164–2170, van SaeneR.H.F.
   Google Scholar
• Beukeveld G. J., In't Veld G., Havinga R., Groen A. K., Wolthers B. G., Kuipers F. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. J. Hepatol 1996; 24: 343–52
   PubMedGoogle Scholar
• Blacow N. W. Drug information centres: a hospital pharmacist's view. Proc. R. Soc. Med. 1977; 70: 250–2
   PubMedGoogle Scholar
• Borenfreund E., De Harven E., Garra L. Mallory body like abnormalities in carcinomas induced by cultured transformed liver cells. Hepatology 1981; 1: 408–415
   PubMedGoogle Scholar
• Borenfreund E., Higgins P. J., Bendich A. In vitro - in vivo rat liver carcinogenesis: modifications in protein synthesis and ultrastructure. Ann. N. Y. Acad. Sci. 1980; 349: 352–357
   Google Scholar
• Borenfreund E., Higgins P J., Steinglass M., Bendich A. Carcinogen induced abnormalities in rat liver cells and their modification by chemical agents. Canc. Res. 1979; 39: 800–807
   PubMedGoogle Scholar
• Brady A. M., Lock E. A. Inhibition of ferrochelatase and accumulation of porphyrins in mouse hepatocyte cultures exposed to porphyrinogenic chemicals. Arch-Toxicol 1992; 66: 175–181
   PubMed Web of Science ®Google Scholar
• Brossi A., Baumann M., Gerecke M., Kyburz E. Totalsynthese vonGriseofulvin. Helv. Chim. Acta 1960; 43: 1444–1447
   Google Scholar
• Bursch W., Lauer B., Timmermann-Trosiener I., Barthel G., Schuppler J., Schulte-Hermann R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984; 5: 453–458
   PubMed Web of Science ®Google Scholar
• Bursch W., Oberhammer F., Schulte-Hermann R. Cell death by apoptosis and its protective role against disease. Trends in Pharmacological Sciences 1992; 13: 245–251
   PubMed Web of Science ®Google Scholar
• Cabaral F., Sobel M. E., Gottesman M. M. CHO-mutants resistant to colchicine, colchicine, or griseofulvin have an altered beta-tubulin. Cell 1980; 20: 29–36
   PubMedGoogle Scholar
• Cabral J. R.P., Shubik P., Mollner T., Raitano F. Carcinogenic activity of hexachlorobenzene. Nature 1977; 269: 510–511
   PubMed Web of Science ®Google Scholar
• Cadrin M., Kawahara H., Ohta, Katsuma Y., Marceau N., French S. W. Mallory bodies in hepatomas and hyperplastic nodules. In vivo and in vitro studies, D. E. Stevenson, J. A. Popp, J. M. Ward, R. M. McClain, T. J. Slaga, H. C. Pitot. Alan R. Liss, New York 1990; 231–248, Mouse Liver Carcinogenesis: Mechanisms and Species Comparisons
   Google Scholar
• Cantoni L., Di Padova C., Rovagnatl P., Ruggieri R., Dal Fiume D., Tritapepe R. Bile secretion and liver microsomal mixed function oxidase system in mice with griseofulvin-induced hepatic protoporphyria. Toxicology 1983; 27: 27–39
   PubMedGoogle Scholar
• Carrano A. V., Thompson L. H. Sister chromatid exchange and gene mutation. Cytogenet-Cell-Genet 1982; 33: 57–61
   PubMedGoogle Scholar
• Cavenee W. K., Dryja T. P., Phillips R. A., Benedict W. F., Goldbart R., Gallie B. L., Murphree A. L., Strong L. C., White R. L. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305: 779–784
   PubMed Web of Science ®Google Scholar
• Cerutti P. A. Prooxidant states and tumor promotion. Science 1985; 227: 375–381
   PubMed Web of Science ®Google Scholar
• Chen H., Rupa D. S., Tomar R., Eastmond D. A. Chromosomal loss and breakage in mouse bone marrow and spleen cells exposed to benzenein vivo. Cancer-Res 1994; 54: 3533–9
   PubMedGoogle Scholar
• Chiou W. L., Riegleman S. Absorption characteristics of solid dispersed and micronized griseofulvin in man. J. Pharm. Sci. 1971; 60(9)1376–1380
   PubMedGoogle Scholar
• Chiprut R. O., Viteri A., Jamroz C., Dyck W. P. intrahepatic cholestasis after griseofulvin administration. Gastroenterology 1976; 70: 1141–43
   PubMed Web of Science ®Google Scholar
• Choi S. W., Han J. H., Lim K. T., Chung K. W., Sun H. S., Park D. H., Kim B. S., Seo E. J. Effect of ursodeoxycholic acid on experimental hepatic porphyria induced by griseofulvin. J. Kor. Med. Sci. 1991; 6: 146–156
   PubMedGoogle Scholar
• Choy W. H., Ts'o P. O.P. Induction of heteroploidy in diploid cells using antimitotic agents. J. Cell Biol. 1981; 91, 383a
   Google Scholar
• Cohen S. M., Ellwein L. B. Genetic errors, cell proliferation, and carcinogenesis. Cancer Research 1991; 51: 6493–6505
   PubMed Web of Science ®Google Scholar
• Cole S. P., Marks G. S. Ferrochelatase and N-alkylated porphyrins. Mol. Cell. Biochem. 1984; 64: 127–137
   PubMedGoogle Scholar
• Cole S. P., Massey T. E., Marks G. S., Racz W. J. Effects of porphyrin-inducing drugs on ferrochelatase activity in isolated mouse hepatocytes. Can. J. Physiol. Pharmacol. 1981; 59: 1155–1158
   PubMedGoogle Scholar
• Columbano A., Dessi S., Ledda Columbano G. M., Chiodino C., Coni P., Pani P., Rao K. N. HMP-shunt and cholesterol metabolism in experimental models involving normal and preneoplastic liver growth. Toxicol. Pathol 1987; 15: 43–50
   PubMedGoogle Scholar
• Cortes J. M., Oliva H., Paradines F. J., Hernandez Guio. The pathology of the liver in porphyria cutanea tarda. Histopathology 1980; 4: 471–485
   PubMed Web of Science ®Google Scholar
• Cripps D. J. Porphyria: genetic and acquired. C. R. Morris. Publ, Lyon 1985; 77: 549–566, Hexachlorbenzene: Proceedings of an International Symposium. IARC Sci.
   Google Scholar
• Cripps D J., Liem H. H., Muller-Eberhard U. Griseofulvin causing hyper-hemopexinemia and hepatic proliferation in mice: anin vivo andin vitro study. J. Inv. Dermatol. 1977; 68(2)82–87
   PubMedGoogle Scholar
• Crossin K. L., Carney D. H. Evidence that micro-tubule depolymerisation early in the cell cycle is sufficient to initiate DNA-synthesis. Cell 1981; 23: 61–78
   PubMed Web of Science ®Google Scholar
• Cullen S. I., Catalano P. M. Griseofulvin - warfarin Antagonism. J. Am. Med. Assoc. 1967; 199: 150–151
   Google Scholar
• Curry P. T., Reed R. N., Martino R. M., Kitchin R. M. Induction of sister chromatid exchangesin vivo in mice by the mycotoxins sterigmatocystin and griseofulvin. Mut. Res. 1984; 137: 111–115
   PubMedGoogle Scholar
• Daya-Grosjean L., Sarasin A., Monier R. Effect of tumor promotion on soft agar growth in Swiss 3T3 cells infected with SV40 ts-A mutants. Carcinogenesis 1982; 3(7)833–835
   PubMedGoogle Scholar
• De Brabander M., Aerts F., Van de Veire R., Borgers M. Evidence against interconversion of microtubules and filaments. Nature 1975; 253: 119–120
   PubMedGoogle Scholar
• De Carli L. Griseofulvin. Mutat. Res. 1988; 195: 91–126
   PubMedGoogle Scholar
• De Matteis F., Abritti G., Gibbs A. H. Decreased liver activity of porphyrin-metal chelatase in hepatic porphyria caused by 3,5–diethoxy-carbonyl-1,4-dihydrochollidine. Studies on rats and mice. Biochem. J. 1973; 134: 717–727
   PubMed Web of Science ®Google Scholar
• De Matteis F., Donnelly A. J., Runge W. J. The effect of prolonged administration of griseofulvin in mice with reference to sex differences. Cancer Res 1966; 26: 721–726
   PubMed Web of Science ®Google Scholar
• De Matteis F. Stimulation of the pathway of porphyrin synthesis in the liver of rats and mice by griseofulvin, 3,5-diethoxycarbonyl-1,4-dihydro-collidine and related drugs: evidence for two basically different mechanisms. Biochem. J. 1975; 146: 285–287
   PubMed Web of Science ®Google Scholar
• De Matteis F. Hypercholesterolaemia and liver enlargement in experimental hepatic porphyria. Biochem. J. 1966; 98: 230–250
   Google Scholar
• De Matteis F. Disturbance of porphyrin metabolism caused by griseofulvin in mice. Brit. J. Dermatol. 1963; 75: 91–104
   PubMed Web of Science ®Google Scholar
• Dehner L. P., Krivit W. Griseofulvin therapy as a cause of lymphnode proliferation resembling malignant histiocytosis. Pediatric Res. 1977; 11: 470
   Google Scholar
• Denk H., Eckersdorfer R. Colchicine induced Mallory body formation in the mouse. Lab. Invest. 1977; 36: 563
   PubMedGoogle Scholar
• Denk H., Abdelfattah-Gad M., Eckerstorfer R., Talcott R. E. Microsomal mixed-function oxidase and activities of some related enzymes in hyper-plastic nodules induced by long-term griseofulvin administration in mouse liver. Canc. Res. 1980; 40: 2568–2573
   PubMed Web of Science ®Google Scholar
• Denk H., Eckerstorfer R., Gschnait F., Konrad K., Wolff K. Experimental induction of hepato-cellular hyalin (Mallory bodies) in mice by griseofulvin treatment. 1. Light microscopic observation. Lab-Invest 1976; 35: 377–82
   PubMedGoogle Scholar
• Denk H., Franke W., Dragosics B., Zeiler I. Pathology of cytoskeleton of liver cells: Demonstration of Mallory bodies in murine and human hepatocytes by immunofluorescence microscopy using antibodies to cytokeratin polypeptides from hepatocytes. Hepatology 1981a; 1: 9–20
   PubMed Web of Science ®Google Scholar
• Denk H., Gschnait F., Wolff K. Hepatocellular hyalin (Mallory bodies) in long term griseofulvin treated mice: a new experimental model for the study of hyalin formation. Lab. Invest. 1975; 32: 773–776
   PubMedGoogle Scholar
• Denk H., Kalt R., Abdelfattah-Gad M., Meyer U. A. Effect of griseofulvin on 5-aminolevulinate synthase and on ferrochelatase in mouse liver neo-plastic nodules. Canc. Res. 1981b; 41: 1535–1538
   PubMedGoogle Scholar
• Denk H., Krepler R., Lackinger E., Artlieb U., Franke W. W. Immunological and biochemical characterisation of the hepatin-related component of Malloy bodies: A pathological pattern of hepatocytic cytokeratins. Liver 1982; 2: 165–175
   PubMedGoogle Scholar
• Diwan B. A., Henneman J. R., Rice J. M., Nims R. W. Enhancement of thyroid and hepatocarcinogenesis by 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene in rats at doses that cause maximal induction of CYP2B. Carcinogenesis 1996; 17: 37–43
   PubMed Web of Science ®Google Scholar
• Ellwein L. B., Cohen S. H. The health risks of saccharin revisited. Crit. Rev. Toxicol. 1990; 20: 311–326
   PubMed Web of Science ®Google Scholar
• El Mofty M. M., Khudoley V. V. Induction of hepatocellular carcinomas in the egyptian toad(Bufo regularis) by an antifungal drug (Griseofulvin). Oncology 1993; 50: 267–269
   PubMedGoogle Scholar
• Epe B., Harttig U., Stopper H., Metzler M. Covalent binding of reactive estrogen metabolites to microtubular protein as a possible mechanism of aneuploidy induction and neoplastic cell transformation. Environm. Health Perspect., 88: 123–7, 19972
   PubMedGoogle Scholar
• Epstein S. S., Andrea J., Joshi S., Mantel N. Hepatocarcinogenicity of griseofulvin following parenteral administration to infant mice. Cancer Res. 1967; 27: 1900–1906
   PubMedGoogle Scholar
• Epstein S. S., Arnold E., Andrea J., Bass W., Bishop Y. Detection of chemical mutagens by the dominant lethal assay in the mouse. Toxicol. Appl. Pharmacol. 1972; 23: 288–325
   PubMed Web of Science ®Google Scholar
• Evans H J. Human lymphocytes for the analysis of chromosome aberrations in mutagen tests. Handbook of Mutagenicity Test Procedures.2nd ed., B. J. Kilbey, M. Legator, W. Nichols, C. Ramel. Elsevier, Amsterdam 1984; 405–428
   Google Scholar
• Faccini J. M., Butler W. R., Friedmann J. C., Hess R., Reznik G. K., Ito N., Hayashi Y., Williams G. M. IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay. Experimental and Toxicologic Pathology 1992; 44: 443–456
   PubMedGoogle Scholar
• Farber E. Hepatocyte proliferation in stepwise development of experimental liver cell cancer. Digestive Diseases and Sciences 1991; 36: 973–978
   PubMedGoogle Scholar
• Franke W. W., Denk H., Schmidt E., Osborn M., Weber K. Ultrastructural, biochemical, and immunological characterisation of Mallory bodies in livers of griseofulvin treated mice. Lab. Invest. 1979; 40: 207–220
   PubMed Web of Science ®Google Scholar
• French S. W., Irie T., Tazawa J., Benson N. C. Electron microscopic study of hepatoma and hyper-plastic nodules induced by griseofulvin in mice. Fed. Proc. 1984; 43: 3169
   Google Scholar
• French S., Sim J., Franks K., Burbidge E., Denton T., Caldwell M. Alcoholic hepatitis. Alcohol and the Liver, M. Fisher, J. Rankin. Plenum Press, New York 1977; 261–268
   Google Scholar
• Friedkin M., Rozengurt E. The role of cytoplasmic microtubules in the regulation of the activity of peptide growth factors. Adv. Enz. Regul. 1981; 19: 39–59
   Google Scholar
• Fucic A., Garaj Vrhovac V., Skara M., Dimitrovic B. X-rays, microwaves and vinyl chloride monomer: their clastogenic and aneugenic activity, using the micronucleus assay on human lymphocytes. Mutat. Res 1992; 282: 265–71
   PubMed Web of Science ®Google Scholar
• Fujita J., Yoshida O., Sugawara K., Ito Y. Enhanced expression of Epstein-Barr virus early antigen by agents in a lately infected human lymphoblastoid cell line. Experientia 1985; 41: 372–373
   PubMedGoogle Scholar
• Gebhart E. Sister chromatid exchange (SCE) and structural chromosome aberration in mutagenicity testing. Hum-Genet 1981; 58: 235–54
   PubMed Web of Science ®Google Scholar
• Gerbracht U., Bursch W., Kraus P., Pub B., Reinacher M., Timmermann-Trosiener I., Schulte-Hermann R. Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver. Carcinogenesis 1990; 11: 617–624
   PubMed Web of Science ®Google Scholar
• Goetz H., Reichberger M. Ergebnisse einer Fragebogenaktion bei 1670 Dermatologen der Bundesrepublik Deutschland uber Nebenwirkungen derGriseofulvintherapie. Hautartzt 1972; 23: 485–492
   PubMedGoogle Scholar
• Goetz H. Side effects of griseofulvin therapy after 12 years experience. Arch. Dermatol. Forsch. 1972; 244: 391–395
   PubMedGoogle Scholar
• Goodman and Gilman's. Eds. The Pharmacological Basis of Therapeutics9th ed, A. Goodman Gilman. Pergamon Press, New York, 1184, Taylor1995
   Google Scholar
• Griesbach R J., Schnabelrauch L. S., Sink K. C. Griseofulvin-induced chromosome instability and reduction in aPetunia somatic hybrid. Journal of the American Society for Horticultural Science 1983; 108: 714–716
   Google Scholar
• Grisham L., Wilson L., Bensch K. Antimitotic action of griseofulvin does not involve disruption of microtubules. Nature 1973; 244: 294–296
   PubMedGoogle Scholar
• Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., Joslyn G., Stevens J., Spirio L., Robertson M. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589–600
   PubMed Web of Science ®Google Scholar
• Grove J. F. Griseofulvin. Q. Rev. Chem. Soc. 1963; 17: 1–19
   Google Scholar
• Gschnait F., Konrad K., Hönigsmann H., Denk H., Wolff K. Mouse model for protoporphyria. 1. The liver and hepatic protoporphyrin crystals. J. Invest. Dermatol. 1975; 65: 290–299
   PubMedGoogle Scholar
• Gudi R., Ritter A. P., Putman D. L. Griseofulvin induced cell division abnormalities in Syrian hamster embryo cells. Environ. Mol. Mutagen. 1996; 27(27)26, Suppl. (abstract
   Google Scholar
• Gupta R. S. Griseofulvin resistance mutation of Chinese hamster ovary cells that affects the apparent molecular weight of a 200 000 Dalton protein. Mol. Cell Biol. 1984; 4: 1761–1768
   PubMedGoogle Scholar
• Hägermark Ö., Berlin A., Walin I., Boreus L. O. Plasma concentration of griseofulvin in healthy volunteers and patients treated for oxychomycosis. Acta Dermatovener. 1976; 56: 289–296
   PubMedGoogle Scholar
• Hard G. C., Whyser J. Risk assessment of D-limonene: An example of male rat specific renal tumorigenesis. Crit. Rev. Toxicol. 1999; 24: 231–254
   Google Scholar
• Hardell L. Aspects of primary liver cancer and its relation to porphyria cutanea trada and porphyria cutanea intermittens. C. R. Moms, J. R.P. Cabral. Publ, Lyon 1985; 77: 591–592, Hexuchlorbenzene: Proceedings of an International SymposiumARC Sci
   Google Scholar
• Hazan R., Denk H., Lackinger E., Schiller D. L. Change of cytokeratin organization during development of Mallory bodies as revealed by a monoclonal antibody. Lab-Invest 1986; 54: 543–53
   PubMedGoogle Scholar
• Heddle J. A., Hite M., Kirkhart B., Mavournin K., MacGregor J. T., Newell G. W., Salamone M. F. The induction of micronuclei as a measure of genotoxicity. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 1983; 123: 61–118
   PubMed Web of Science ®Google Scholar
• Hendrich S., Glauert H. P., Pitot H. C. The phenotypic stability of altered hepatic foci: effects of withdrawal and subsequent readministration of phenobarbital. Carcinogenesis 1986; 7: 2041–2045
   PubMedGoogle Scholar
• Hill R. N., Erdreich L. S., Paynter O. E., Roberts P. A., Rosenthal S. L., Wilkinson C. F. Thyroid follicular cell carcinogenesis. Fundam-Appl-Toxicol 1989; 12: 629–97
   PubMedGoogle Scholar
• Hisia Y., Oshima M., Kitahori Y., Yuasa T., Fujita T., Iwata C. Promoting effects of 3-amino-1,2,4-triazole on the development of thyroid tumors in rats treated with N-bis(2-hydroxypropyI)nitrosamine. Carcinogenesis 1982; 3: 381–384
   PubMedGoogle Scholar
• Holley A. E., Frater Y., Gibbs A. H., De Matteis F., Lamb J. H., Farmer P. B., Naylor S. Isolation of two N-monosubstituted protoporphyrins, bearing either the whole drug or a methyl group on the pyrrole nitrogen atom, from liver of mice given griseofulvin. Biochem-J 1991; 274: 843–848
   PubMedGoogle Scholar
• Hoover R., Fraumeni J. F. Drug induced cancer. Cancer 1981; 47(5)1071–1080
   PubMedGoogle Scholar
• Horng C. B., Bruce S. A., Ts'o P. O. A comparative study on neoplastic transformation of human and Syrian hamster cells. Proc. Natl. Sci. Counc. Rep. China 1985; 9: 255–268
   PubMedGoogle Scholar
• Hoso M. Cytophotometric DNA-analysis of hepatocellular carcinoma with Mallory bodies. Virch. Arch. A Pathol. Anatomy 1989; 416: 51–55, Nakanuma
   PubMedGoogle Scholar
• Huff J., Lucier G., Tritscher A. Carcinogenicity of TCDD— experimental, mechanistic, and epidemiologic evidence. Annual Review of Pharmacology and Toxicology 1994; 34: 343–372
   PubMed Web of Science ®Google Scholar
• IARC. Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Some naturally occuring substances 1976; 10: 153–161
   Google Scholar
• IARC. Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. 1987; 7, Suppl.
   Google Scholar
• Ihrig T. J., Benson N. C., French S. W. Liver injury due to griseofulvin: Gammaglutamyltranspeptidase induction correlated with Mallory bodies. Fed. Proc. 1980; 39: 877
   Google Scholar
• Irie T., Benson N. C., French S. W. Relationship of Mallory bodies to the cytoskeleton of hepatocytes in griseofulvin treated mice. Lab. Invest. 1982; 47: 336–345
   PubMedGoogle Scholar
• Ito N., Hananouchi M., Sugihara S., Shirai T., Tsuda H., Fukushima S., Nagasaki H. Reversibility and irreversibility of liver tumors in mice induced by the alpha isomer of 1,2,3,4,5,6- hexachlorocyclohexane. Cancer Research 1976; 36: 2227–2234
   PubMedGoogle Scholar
• Jensen K., Gluud C. The Mallory body: morphological, clinical and experimental studies (part 1 of a literature survey). Hepatology 1994a; 20(4)1061–1077, No.
   PubMedGoogle Scholar
• Jensen K., Gluud C. The Mallory body: theories on development and pathological significance (part 2 of a literature survey). Hepatology 1994b; 20(5)1330–1342
   PubMedGoogle Scholar
• Jensen K. G., Onfelt A., Poulsen H. E., Doehmer J., Loft S. Effects of Benzo[a]pyrene and (O-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene on mitosis in Chinese hamster V79 cells with stable expression of rat cytochrome P4501Al or 1A2. Carcinogenesis 1993; 14: 2115–2118
   PubMed Web of Science ®Google Scholar
• Kappas A., Granick S. Experimental hepatic porphyria. Studies with steroids of physiological origin in man. Am. N.Y. Acad. Sci. 1968; 151: 842
   PubMedGoogle Scholar
• Kappas A., Sassa S., Galbraith R. A., Nordmann. The porphyrias. The metabolic basis of inherited disease, C. R. Scriver, D. Valle. McGraw-Hill, New York 1989; 1305–1365, BaudetA.L., Eds
   Google Scholar
• Katsuma Y., Swierenga S. H.H., Khettry U., Marceau N., French S. W. Changes in the cytokeratin intermediate filament cytoskeleton associated with Mallory body formation in mouse and human liver. Hepatology 1987; 7: 1215–1223
   PubMedGoogle Scholar
• Kerler R., Rabes H. M. Preneoplastic rat liver cellsin vitro: Slow progression without promoters, hormones, or growth factors. Journal of Cancer Research and Clinical Oncology 1988; 114: 113–123
   PubMedGoogle Scholar
• Kimbrough R. D., Squire R. A., Linder R. E., Strandberg J. D., Montali J., Burse V. W. Introduction of liver tumors in Sherman strain female rats by polychlorinated biphenyl Aroclor 1260. JNCI 1975; 55: 1453–1459
   PubMedGoogle Scholar
• Kimoff R. J., Huang S. Immunocytochemical and immunoelectron microscopic studies on Mallory bodies. Lab-Invest 1981; 45: 491–503
   PubMedGoogle Scholar
• Kinsella A. R. Elimination of metabolic cooperation and the induction of SCEs are not properties common to all promoting or cocarcinogenic agents. Carcinogenesis 1982; 3: 499–504
   PubMed Web of Science ®Google Scholar
• Kirby G. M., Pelkonen P., Vatanasapt V., Camus A. M., Wild C. P., Lang M. A. Association of liver fluke (Opisthorchis viverrini) infestation with increased expression of cytochrome P450 and carcinogen metabolism in male hamster liver. Mol-Carcinog 1994; 11: 81–89
   PubMedGoogle Scholar
• Klein M. F., Beall J. R. Griseofulvin: a teratogenic study. Science 1972; 175: 1483–1484
   PubMed Web of Science ®Google Scholar
• Klopman G., Rosenkranz H. S. Approaches to SAR in carcinogenesis and mutagenesis. Prediction of carcinogenicity/mutagenicity using MULTICASE. Mutat. Res. 1994; 305: 33–46
   PubMed Web of Science ®Google Scholar
• Klopman G., Rosenkranz H. S. Testing by artificial intelligence: Computational alternatives to the determination of mutagenicity. Mutat. Res. 1991; 272: 59–71
   Google Scholar
• Knudson A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1971; 68: 820–823
   PubMed Web of Science ®Google Scholar
• Kochendorfer U. Stöorungen des Zellzyklus durch Anomalien des Spindelapparates. 1993, Endogene und exogene Induktion von quantitativen und qualitativen Veranderungen. Doctoral ThesisBonnFRG
   Google Scholar
• Kociba R. J., Keyes D. G., Beyer J. E., Carreon R. M., Wade C. E., Dittenber D. A., Kalnins R. P., Frauson L. E., Park C. N., Barnard S. D., Hummel R. A., Humiston C. G. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol. Appl. Pharmacol. 1978; 46: 279–303
   PubMed Web of Science ®Google Scholar
• König E., Berthold K., Hienz H. A., Brittinger G. Griseofulvin and chronic granulocytic leucemia. Helv. Med. Act. 1969; 35: 103–107
   PubMedGoogle Scholar
• Kordac V., Martasek P., Zoubek V., Kalab M. Porphyria cutanea tarda. Manifestation and therapy. Ann. N.Y. Acad. Sci. 1987; 514: 335–336
   Google Scholar
• Kraupp-Grasl B., Huber W., Taper H., Schulte-Hermann R. Increased Susceptibility of Aged Rats to Hepatocarcinogenesis by the Peroxisome Proliferator Nafenopin and the Possible Involvement of Altered Liver Foci Occurring Spontaneously. Cancer Research 1991; 51: 666–671
   PubMed Web of Science ®Google Scholar
• Larizza L., Doneda L., Colotta F., Mantovani A. Enhanced proliferation and prolonged in vitro life span of human monocytes in conditioned medium from a murine fibrosarcoma line. 1986; 79, Normal and Neoplastic Blood Cells: from Genes to Therapy, Symposium Abstract
   Google Scholar
• Larizza L., Simoni G., Stefanini M., De Carli L. Induced heteroploidy and cell transformation. Biochem Exptl. Biol. 1976; 12: 433–440
   Google Scholar
• Larizza L., Simoni G., Stefanini M., De Carli L. Spontaneous and griseofulvin-induced segregation for 8-azaguanine resistance in hybrids from a human heteroploid line. Exp. Cell Res. 1979; 120: 405–409
   PubMed Web of Science ®Google Scholar
• Larizza L., Simoni G., Tredici F. Griseofulvin: a potential agent of chromosomal segregation in cultured cells. Mutat-Res 1974; 25: 123–30
   PubMed Web of Science ®Google Scholar
• Latt S. A. Sister chromatid exchange formation. Annu-Rev-Genet 1981; 15: 11–55
   PubMed Web of Science ®Google Scholar
• Leonard A., Poncelet F., G rut man G., Carbonelle E., Fabry L. Mutagenicity tests with griseofulvin. Mutat. Res 1979; 68: 225–234
   PubMedGoogle Scholar
• Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature 1991; 351: 453–6
   PubMed Web of Science ®Google Scholar
• Lin J. J., Gonzalez A., Banerjee S., Banerjee S. K., Li S. A. Estrogen carcinogenesis in the hamster kidney: role of cytotoxicity and cell proliferation. Environm. Health Perspect 1991; 101(5)259–64, Suppl
   Google Scholar
• Lin C. C., Chang R., Casmer C., Symchowicz S. Effects of phenobarbital, 3-methylcholanthrene and griseofulvin on the o-demethylation of griseofulvin by liver microsomes of rats and mice. Drug. Metabol. Disp. 1973a; 1: 611–618
   PubMed Web of Science ®Google Scholar
• Lin C. C., Magat J., Chang R., McGlotten J., Symchowicz S. Absorption, metabolism and excretion of14C-griseofulvin in man. J. Pharmacol. Exptl. Ther. 1973b; 187: 415–422
   PubMed Web of Science ®Google Scholar
• Lin C. C., Symchowicz S. Absorption, distribution, metabolism and excretion of griseofulvin in man and animals. Drug Metabol. Rev. 1975; 4(1)75–95
   PubMed Web of Science ®Google Scholar
• Linnik A. B. Experimental study on the possible role of griseofulvin in carcinogenesis. Vestn. Derm. Vener. 1972; 46: 49–51
   PubMedGoogle Scholar
• Lithner F., Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta. Med. Scand. 1984; 215: 271–274
   PubMedGoogle Scholar
• Lo Schiavo F., Nuti Ronchi V., Terzi M. Genetic effects of griseofulvin on plant cell cultures. Theor. Appl. Genet. 1980; 58: 43–47
   PubMedGoogle Scholar
• Lowe J., Blanchard A., Morrell K., Lennox G., Reynolds L., Billett M., Landon M., Mayer R. J. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J-Pathol 1988; 155: 9–15
   PubMed Web of Science ®Google Scholar
• MacLeod J., Nelson W. O. Griseofulvin and human spermatogenesis. Proc. Soc. Exp. Med. Biol. 1960; 102: 259–260
   Google Scholar
• Mailhes J. B., Marchetti F., Aardema M. J. Griseofulvin induced aneuploidy and meiotic delay in mouse oocytes: effects of dose and harvest time. Mutat. Res. 1993; 300: 155–163
   PubMedGoogle Scholar
• Mallory F. B. Cirrhosis of the liver: five different lesions from which it may arise. Bull. John Hopkins Hosp. 1911; 22: 69
   Google Scholar
• Marchetti F., Mailhes J. B. Variation of mouse oocyte sensitivity to griseofulvin induced aneuploidy during the first meiotic division. Env. Molec. Mutagens. 1994; 23: 179–185
   PubMedGoogle Scholar
• Marchetti F., Mailhes J. B. Variation of mouse oocyte sensitivity to griseofulvin induced aneuploidy during the second meiotic division. Mutagenesis 1995; 10: 113–121
   PubMedGoogle Scholar
• Marks G. S., Powles J., Lyon M., McCluskey S., Sutherland E., Zelt D. Patterns of porphyrin accumulation in response to xenobiotics. Parallels between results in chick embryo and rodents. Am. N.-Y. Acad. Sci 1987; 514: 113–27
   PubMedGoogle Scholar
• Marvel J. R., Schlichting D. A., Denton C., Levy E. J., Cahn M. M. The effect of surfactant and of particle size on griseofulvin plasma levels. J. Invest. Dermatol. 1964; 142: 197–203
   Google Scholar
• Matilla A., Molland E. A. A light and electron microscopic study of the liver in case of erythrohepatic protoporphyria and in griseofulvin-induced porphyria in mice. J. Clin. Pathol. 1974; 27: 698–709
   PubMed Web of Science ®Google Scholar
• The signifiance of hepatic microsomal enzyme induction and altered enyzyme function in rats: implications for thyroid gland neoplasia. Tonic Pathology 1989; 17: 294–306, McClain
   Google Scholar
• McIntosh D. A.D., Topham J. C. A comparison of mouse and rat liver enzymes and their response to treatment with various compounds. Biochem. Pharmacol. 1972; 21: 1025–1029
   PubMed Web of Science ®Google Scholar
• MacLeod J., Nelson W. O. Griseofulvin and human spermatogenesis. Proc. Soc. Exp. Med. and Biology 1960; 102: 259–260
   Google Scholar
• Medoff G., Kobayashi G. Mode of action of antifungal drugs. VII. Griseofulvin. Fungi Pathogenic for Humans and Animals. Part B. Pathogenicity and Detection, D. H. Howard. Marcel Dekker Inc, NY 1983; 345–355
   Google Scholar
• Meierhenry E. F., Ruebner B. H., Gershwin M. E., Hsieh L. S., French S. W. Mallory body formation in hepatic nodules of mice ingesting dieldrin. Lab. Invest. 1981; 44: 392–396
   PubMedGoogle Scholar
• Melnick R. L. Does chemically induced hepatocyte proliferation predict liver carcinogenesis. FASEB Journal 1992; 6: 2698–2706
   PubMed Web of Science ®Google Scholar
• Metneki J., Czeizel A. The Lancer 1987; 2: 1042, Griseofulvin teratology, May
   Google Scholar
• Morris H. P. The experimental development and metabolism of thyroid gland tumors. Adv. Cancer Res. 1955; 3: 51–115
   PubMedGoogle Scholar
• Muccinelli A., Sanguinetti F. [Effect of the administration of copper salts on cholesteremia and beta-lipoproteinemia in rats treated with griseofulvin]. Boll-Soc-Ital-Biol-Sper 1967; 43: 1651–2
   PubMedGoogle Scholar
• Nagasaki H., Tomii S., Mega T., Marugami M., Ito N. Hepatocarcinogenicity of polychlorinated biphenyls in mice. GANN 1972; 63: 805
   PubMedGoogle Scholar
• Nakanuma Y., Ohta G. Is mallory body formation a preneoplastic change? A study of 181 cases of liver bearing hepatocellular carcinoma and 82 cases of cirrhosis. Cancer 1985; 55: 2400–2404
   PubMedGoogle Scholar
• Nakao K., Wada O., Takaku F., Sassa S., Yamo Y., Urata G. The origin of the increased protoporphyria in erythrocytes of mice with experimentally induced porphyria. J. Lab. Clin. Med. 1967; 70: 923–932
   PubMedGoogle Scholar
• Namba M., Kimoto T. Cytotoxic effects of griseofulvin on human normal cellsin vitro. Kawasaki Med.J. 1976; 2: 127–134
   Google Scholar
• Navone N. M., Buzaleh A. M., Polo C. F., Afonso S. G., Vazquez E. S., Batlle A. M. The effect of griseofulvin on the heme pathway—II. An exhaustive analysis during short and long-term challenge. Gen-Pharmacol 1991; 22: 1179–83
   PubMedGoogle Scholar
• Ohmori T., Rice J. M., Williams G. M. Histochemical characteristics of spontaneous and chemically induced hepatocellular neoplasms in mice and the development of neoplasms with gamma-glutamyl transpeptidase activity during phenobarbital exposure. Histochem-J 1981; 13: 85–99
   PubMedGoogle Scholar
• Ohshima H., Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat-Res 1994; 305: 253–64
   PubMed Web of Science ®Google Scholar
• Okino K., Weibert R. T. Warfarin-Griseofulvin interaction. Drug. Intell. Clin. Pharm. 1986; 20: 291–294
   PubMedGoogle Scholar
• Oshimura M., Barrett J. C. Chemically induced aneuploidy in mammalian cells: Mechanisms and biological significance in cancer. Env. Mutagen 1986; 8: 129–159
   PubMedGoogle Scholar
• Otto A. M., Ulrich M. O., Zombe A., Jimenez de Asua L. Microtubule disrupting agents affect two different events regulating the initiation of DNA-synthesis in Swiss 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 1981; 78(5)3063–3067
   PubMedGoogle Scholar
• Oxford A. E., Raistrick H., Simonart P. Griseofulvin—a metabolic product of. Penicilium griseofulvum dierckr., Biochem. J. 1939; 33: 240–248
   PubMedGoogle Scholar
• Paget G. E., Alcock S. J. Griseofulvin and colchicine: Lack of carcinogenic action. Nature 1960; 188: 867
   PubMedGoogle Scholar
• Paget G. E., Walpole A. L. Some cytological effects of griseofulvin. Nature 1958; 182: 1320–1321
   PubMedGoogle Scholar
• Peters R. S. Patology of hepatocellular carcinoma. Hepatocellular Carcinoma, K. Okuda, R. Peters. Wiley & Sons, NY 1976; 107–168
   Google Scholar
• Parzefall W., Schuppler J., Barthel G., Meyer Rogge B., Schulte Hermann R. Toxicological studies on a benzofurane derivative. I. A comparative study with phenobarbital on rat liver. Toxicol-Appl-Pharmacol 1990; 106: 482–99
   PubMedGoogle Scholar
• Pierach C. A. Porphyria and hepatocellular carcinoma. Brit. J. Canc. 1987; 59: 111
   Google Scholar
• Pilot H. C. Progression—the terminal stage in carcinogenesis. Japanese Journal of Cancer Research 1989; 80: 599–607
   PubMedGoogle Scholar
• Poland A., Knudson J. C. 2, 3, 7, 8-tetrachloro-dibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annual Review of Pharmacology and Toxicology 1982; 22: 517–554
   PubMed Web of Science ®Google Scholar
• Preisegger K. H., Stumptner C., Riegelnegg D., Brown P. C., Silverman J. A., Thorgeirsson S. S., Denk H. Experimental Mallory body formation is accompanied by modulation of the expression of multidrug-resistance genes and their products. Hepatology 1991; 24: 248–52
   Google Scholar
• Preisegger K. H., Zatloukal K., Spurej G., Riegelnegg D., Denk H. Common epitopes of human and murine Mallory bodies and Lewy bodies as revealed by a neurofilament antibody. Lab-Invest 1992; 66: 193–9
   PubMedGoogle Scholar
• Raimondi E., Scariolo S., De Sario A., De Carli L. Aneuploidy assays on interphase nuclei by means ofin situ hybridisation with DNA-probes. Mutagenesis 1989; 4: 165–169
   PubMedGoogle Scholar
• Rao K. N. The significance of the cholesterol bio-synthetic pathway in cell growth and carcinogenesis (review). Anticancer-Res 1995; 15: 309–14
   PubMed Web of Science ®Google Scholar
• Redeker A. G., Sterling R. E., Bronow R. S. Effect of griseofulvin in acute intermittent porphyria. J. Am. Med. Assoc 1964; 188: 466–468
   Google Scholar
• Rimington C., Morgan P. N., Nicholls K., Everall J. D., Davies R. R. Griseofulvin administration and porphyrin metabolism. Lancet 1963; 17: 318–322, Aug
   Google Scholar
• Rijhsinghani K. S., Abraham C., Swerdiow M. A., Rao K. V. Induction of neoplastic lesions in the livers of C57BL × C3HF1 mice by chloral hydrate. Cancer-Detect-Prev 1986; 9: 279–88
   PubMedGoogle Scholar
• Roobol A., Pogson C J. Inhibition by griseofulvin of microtubule assemblyin vitro. FEBS. Lett. 1976; 67: 248–251
   PubMedGoogle Scholar
• Rosa F. W., Hernandez G., Carlo W. A. Griseofulvin teratology including two thoracopagus conjoined twins. Lancet 1987; 1(8525)171
   PubMedGoogle Scholar
• Rosin H., Antibiotika, Chemotherapeutika. Antiinfektiose Therapie. Allgemeine und spezielle Phamkologie und Toxikologie, W. Forth, D. Henschler, W. Rummel, K. Starke. BI-Wissenschafts-verlag. 1992; 687–688
   Google Scholar
• Rowland M., Riegelman S., Epstein W. L. Absorption kinetics of griseofulvin in man. J. Pharmaceut. Sci. 1968; 57: 984–989
   PubMed Web of Science ®Google Scholar
• Rozengurt R. Growth factors, cell proliferation and cancer: an overview. Mol. Biol. Med. 1983; 1: 169–181
   PubMedGoogle Scholar
• Rubin A., Dvornik D. Placental transfer of griseofulvin. Amer. J. Obstet. Gynec. 1965; 92: 882–883
   PubMedGoogle Scholar
• Russel D., Russel A. D. Treatment of ringworm: old remedy vesus new. J. Infect. 1992; 24: 333
   PubMedGoogle Scholar
• Rustia M., Shubik P. Thyroid tumors in rats and hepatomas in mice after griseofulvin treatment. Br. J. Canc. 1978; 38: 237–249
   PubMedGoogle Scholar
• Salonpäa U P., Krause K., Pelkonen O., Raunio H. Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Naunyn-Schmiede-bergs Arch. Pharmacol. 1995; 351: 446–452
   PubMed Web of Science ®Google Scholar
• Sandow J., Rechberg W. 1990, Griseofulvin: Subchro-nische orale Verträglichkeitspriifung. Hochst Report, No. 891571
   Google Scholar
• Schiffmann D., De Boni U. Dislocation of chromatin elements in prophase induced by diethylstilbestrol: a novel mechanism by which micronuclei can arise. Mutat. Res 1991; 246: 113–22
   PubMedGoogle Scholar
• Schmaehl D. Iatrogenic carcinogenesis. J. Canc. Res. Clin. Oncol. 1981; 99: 71–75
   PubMedGoogle Scholar
• Schulte-Hermann R. Induction of liver growth by xenobiotic compounds and other stimuli. Critical Rev. Toxicol. 1974; 3: 97–158
   Google Scholar
• Schulte-Hermann R. Tumor promotion in the liver. Arch. Toxicology 1985; 57: 147–158
   PubMed Web of Science ®Google Scholar
• Schulte-Hermann R., Bursch W., Kraupp-Grasl B., Oberhammer F., Wagner A., Jirtle R. Cell proliferation and apoptosis in normal liver and preneoplastic foci. Environmental Health Perspectives 1993; 101: 87–90
   PubMed Web of Science ®Google Scholar
• Schulte-Hermann R., Ohde G., Schuppler J., Timmermann Trosiener I. Enhanced proliferation of putative preneoplastic cells in rat liver following treatment with the tumor promoters phenobarbital, hexachlorocyclohexane, steroid compounds, and nafenopin. Cancer Res. 1981; 41: 2556–2562
   PubMed Web of Science ®Google Scholar
• Schulte-Hermann R., Timmermann-Trosiener I., Schuppler J. Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumor production by nonmutagenic compounds. Cancer Res. 1983; 43: 839–844
   PubMed Web of Science ®Google Scholar
• Schulte-Hermann R., Timmermann-Trosiener I., Barthel G., Bunch W. DNA synthesis, apoptosis and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Research 1990; 50: 5127–5135
   PubMed Web of Science ®Google Scholar
• Scott F. W., LaHunta A., Schultz R. D., Birkner S. I., Riis R. C. Teratogenesis in cats, associated with griseofulvin therapy. Teratology 1975; 2: 79–86
   Google Scholar
• Seglen P. O., Gerlyng P. Growth-related alterations during liver carcinogenesis - effect of promoters. Environmental Health Perspectives 1990; 88: 197–205
   PubMedGoogle Scholar
• Seif R. Factors which disorganize microtubules or microfilaments increase the frequency of cell transformation by polyoma virus. J. Virol. 1980; 36: 421–428
   PubMed Web of Science ®Google Scholar
• Sewall C. H., Flagler N., Vanden J. P., Clark G. C., Tritscher A. M., Maronpot R. M., Lucier G. W. Alterations in thyroid function in female Sprague-Dawley rats following chronic treatment with 2,3,7,8–tetrachlorodibenzo-p-dioxin. Toxicol-Appl-Pharmacol 1995; 132: 237–44
   PubMed Web of Science ®Google Scholar
• Shah V. P. Griseofulvin - absorption per Os and percutaneous. Medical Mycology Zbl. Bact., Suppl. 8 1980; 223–239
   Google Scholar
• Shimoyama T., Nonaka S. Biochemical studies on griseofulvin induced protoporphyria, Ann. NY. Acad. Sci. 1987; 514: 160–169
   PubMedGoogle Scholar
• Shimoyama T., Nonaka S., Honda T., Murayama F., Ohgami T., Yoshida H. A biochemical study on experimental porphyria I. The influence of griseofulvin at various concentrations on porphyrin metabolism. J. Dermatol. 1984; 11: 49–55
   PubMedGoogle Scholar
• Sideropoulos A S., Kacsuta P., Betz M. K. Mutations induced by substituted quinolines in UV-irradiated bacteria. Current Microbiol. 1980; 3: 207–212
   PubMedGoogle Scholar
• Siracusa G., Whittigham D. G., DeFelici M. The effect of microtubule and microfilament disrupting drugs on Preimplantation mouse embryos. J. Embr. Exp. Morph. 1980; 60: 71–82
   PubMedGoogle Scholar
• Slonitskaya N. N. Embryotoxic and teratogenic effects of isogriseofulvin-forte at various stages of rat embryogenesis. Antibiotiki 1973; 18: 655–659, Mikhailets
   PubMedGoogle Scholar
• Slonitskaya N. N. Teratogenic effects of griseofulvin-forte on rat fetus. Antibiotiki 1969; 11: 44–48
   Google Scholar
• Smith A. G., De Matteis F. Drugs and the hepatic porphyrias. Clin-Haematol. 1980; 9: 399–425
   PubMedGoogle Scholar
• Biochem. Pharmacol 1990; 40: 2059–68, Smith, A. G., Francis, J.E., Green, J.A., Greig, J.B., Wolf, C.R. and Manson, M.M., Sex-linked hepatic uroporphyria and the induction of cytochromes P450IA in rats caused by hexachlorobenzene and polyhalogenated biphenyls.
   PubMed Web of Science ®Google Scholar
• Smith A. G., Dinsdale D., Manson M. M., Cabral J. R.P. Hepatocarcinogenicity of hexachlorobenzene in rats and sex difference in hepatic iron states and development of porphyria. Carcinogenesis 1985; 6: 631–636
   PubMed Web of Science ®Google Scholar
• Steelman L. R. Determination of the teratogenic and mutagenic potential of griseofulvin. Toxicol. Appl. Pharmacol. 1978; 45: 343–344
   Web of Science ®Google Scholar
• Stolley P. D. Drugs and cancer in humans. Preventive Med. 1980; 9: 202–205
   PubMedGoogle Scholar
• Stout D. L., Becker F. F. Heme enzyme patterns in rat liver nodules and tumors. Canc. Res. 1987; 47: 963–965
   PubMedGoogle Scholar
• Symchowicz S., Katchen B. Griseofulvin absorption in man after single and repeated treatment and its correlation with dissolution rates. J. Pharmaceut. Sci. 1968; 57: 1383–1386
   PubMed Web of Science ®Google Scholar
• Tanaka K., Ohgami T., Nonaka S. Experimental murine protoporphyria induced by griseofulvin: The relationship between hepatic porphyrin levels and liver function test values in mice treated with griseofulvin. J. Dermatol., 20: 545–553, 199227.
   PubMedGoogle Scholar
• Tangeras A. Effect of decreased ferrochelatase activity on iron and porphyrin content in mitochondria of mice with porphyria induced by griseofulvin. Biochim. Biophys. Acta 1986; 882: 77–84
   PubMedGoogle Scholar
• Tazawa J., Ihrig T., French S. W. Mallory body formation runs parallel to gamma-glutamyl transferase induction in hepatocytes of griseofulvin mice. Hepatology 1983; 3: 989–1001
   PubMedGoogle Scholar
• Terzi M., Hawkins T. S.C. Chromosomal variation and the establishment of somatic cell lines invitro. Nature 1975; 253: 361–362
   PubMedGoogle Scholar
• Thomsett L. R. Fungal diseases of the skin of small animals. Brit. Vet. J. 1986; 142: 317–325
   PubMedGoogle Scholar
• Tiveron C., Marchetti F., Bossoni B., Pacchierotti F. Griseofulvin induced aneuploidy and meiotic delay in female mouse germ cells, I. Cytogenetic analysis of metaphase II oocytes. Mutat. Res. 1992; 266: 143–150
   PubMedGoogle Scholar
• Topham J. C., McIntosh D. A., Platt D. S. Biochemical changes in rat liver in response to treatment with drugs and other agents. Biochem-Pharmacol 1972; 21(IV)1019–24
   PubMedGoogle Scholar
• Tsunoo C., Harwood T. R., Arak S., Yokoo H. Cytoskeletal alterations leading to Mallory body formation in livers of mice fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine. J-Hepatol 1987; 5: 85–97
   PubMedGoogle Scholar
• Udall J. A. Drug interference with warfarin therapy. Clinical Medicine 1970; 77: 20–25
   Web of Science ®Google Scholar
• Van Heyningen V. Wilms' tumour: reconciling genetics and biology. Trends in Genet 1992; 8: 16–21
   PubMedGoogle Scholar
• Vesselinovitch S. D., Mikailovitch N. The inhibitory effect of griseofulvin on the promotion of skin carcinogenesis. Canc. Res. 1968; 28: 2463–2465
   PubMed Web of Science ®Google Scholar
• Wada O., Toyokawa K., Urata G., Yano Y., Nakao K. Cholesterol biosynthesis in the liver of experimentally induced porphyric mice. Biochem-Pharmacol 1969; 18: 1533–5
   PubMedGoogle Scholar
• Wada O., Yano Y., Urata G., Nakao K. Behaviour of hepatic cytochromes after treatment of mice with drugs known to disturb porphyrin metabolism in liver. Biochem. Pharmacol. 1968; 17: 595–603
   PubMed Web of Science ®Google Scholar
• Wang A. Interplay of cyclic AMP and microtubules in modulating the initiation of DNA synthesis in 3T3 cells. J. Cell Biol. 1983; 96: 1743–1750, RozengurtE.
   PubMed Web of Science ®Google Scholar
• Wasti U. M., Lang M. A., Bursch W., Camus-Randon A. M., Schulte-Hermann R. Expression of cytochrome P450 2A5 in normal liver, preneoplastic foci and liver tumors of different mouse strains. Toxicol. Appl. Pharmacol., (submitted).
   Google Scholar
• Watson C J., Bossenmaier I., Cardinal R. Griseofulvin and porphyrin metabolism. Arch. Derm. 1968; 98: 451–468
   PubMedGoogle Scholar
• Wehland I., Herzog W., Weber K. Interaction of griseofulvin with microtubules, microtubuli protein and tubulin. J. Molec. Biol. 1977; 111: 329–342
   PubMedGoogle Scholar
• Weinberg R. A. Tumor suppressors genes. Science 1991; 254: 1138–1146
   PubMed Web of Science ®Google Scholar
• Weston-Hurst E., Paget G. E. Protoporphyrin, cirrhosis and hepatomata in the livers of mice given griseofulvin. Brit J. Derm. 1963; 75: 105–112
   Google Scholar
• Wetzl W. J., Alexander R. W. Fowl nodular hyperplasia of the liver with alcoholic hyaline bodies and cytologic atypia. Cancer 1979; 44: 1322–1326
   PubMedGoogle Scholar
• Whittaker S. G., Wilson D., Faustmann. Griseofulvin and estramustine induce mitotic arrest in rat embryonic limb bud cultures. Toxicologist 1993; 13: 257
   Google Scholar
• Whittaker S. G., Zimmermann F. K., Dicus B., Piegorsch W. W., Fogel S., Resnick M. A. Detection of induced mitotic chromosome loss inSaccharomyces cervisiae an interlaboratory study. Mutat. Rex 1989; 224: 31–78
   PubMedGoogle Scholar
• Williams G. M., Ohmori T., Katayama S., Rice J. M. Alteration by phenobarbital of membrane associated enzymes including gamm glutamyl transpeptidase in mouse liver neoplasms. Carcinogenesis 1980; 1: 813–818
   PubMed Web of Science ®Google Scholar
• Williams M. T., Simonet L. Effects of griseofulvin on enzymes associated with phase I and II of drug metabolism. Biochem-Pharmacol 1986; 35: 2630–2632
   PubMedGoogle Scholar
• Wilson L., Bamburg J. R., Mizel S. B., Grisham L. M., Creswell K. M. Interaction of drugs with microtubuli proteins. Fed. Proc. 1974; 33: 158–166
   PubMedGoogle Scholar
• Winterhoff H., Sourgens H. The predictive value of animal experiments in the detection of side effects of drugs on thyroid function. Pharmac. Ther. 1979; 5: 325–332
   Google Scholar
• Wong P. T.T., Cadrin M., French S. W. Distinctive infrared spectra features in liver tumor tissue of mice. Exp. Molec. Pathol. 1991; 55: 269–284, Evidence of structural modifications at the molecular level
   PubMedGoogle Scholar
• Wyrobek A. J., Bruce W. R. Chemical induction of sperm abnormalities in mice. Proc. Natl. Acad. Sci. USA 1975; 72: 4425–4429
   PubMed Web of Science ®Google Scholar
• Wyrobek A J. The induction of sperm-shape abnormalities in mice and humans. Chemical Mutagens - Principles and Methods for their Detection, A. Hollaender, 1982; VII: 257–285, and Ed.
   Google Scholar
• Xu G. F., O'Connell P., Viskochil D., Cawthon R., Robertson M., Culver M., Dunn D., Stevens J., Gesteland R., White R. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990; 62: 599–608
   PubMed Web of Science ®Google Scholar
• Yager J. D., Zurlo J., Nan N. Sex hormones and tumor promotion in liver. Froc. Soc. Exp. Biol. Med. 1991; 667–674
   PubMedGoogle Scholar
• Yokoo H., Craig R. M., Harwood T. R., Cochrone C. Griseofulvin-induced cholestasis in Swiss Albino mice. Gastroenterology 1979; 77: 1082–1087
   PubMedGoogle Scholar
• Yokoo H., Harwood T. R., Racker D., Arak S. Experimental production of Mallory bodies in mice by diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidine. Gastroenterology 1982; 83: 109–13
   PubMed Web of Science ®Google Scholar
• Zatloukal K., Denk H., Lackinger E., Rainer I. Hepatocellular cytokeratins as substrates of transglutaminases. Lab-Invest 1982; 61: 603–8
   Google Scholar
• Zatloukal K., Denk H., Spurej G., Lackinger E., Preisegger K. H., Franke W. W. High molecular weight component of Mallory bodies detected by a monoclonal antibody. Lab-Invest 1990; 62: 427–34
   PubMedGoogle Scholar
• Zawirska B., Bednarz W. The particular trais of carcinogenesis induced in wister rats by Aflatoxin B1, III, Porphyrins and the activity of gamma-glutamyl-transpeptidase in hepatomas and in their tissue of origin. Neoplasma 1981; 28: 35–49
   PubMedGoogle Scholar
• Zbinden G. Hyperplastic and neoplastic responses of the thyroid gland in toxicological studies. Arch. Toxicol. Suppl. 1988; 12: 98–106
   Google Scholar
• Zhang Y. P., Sussman N., Macina O. T., Rosenkranz H. S., Klopman G. Prediction of the carcinogenicity of a second group of organic chemicals undergoing carcinogenicity testing. Environmental Health Perspectives 1996; 104(Suppl 5)1045–1050
   PubMedGoogle Scholar